HOME ·

R&D Progress

HENGRUI PHARMA (01276.HK): HRS-4729 Injection Approved for Phase II Clinical Trial in Type 2 Diabetes
Tags：
HENGRUI PHARMA01276.HKR&D Progress
2026-08-12
IMPACT THERAP-B (07630.HK): Nominates IMP2794 as preclinical candidate compound, first KAT6A-specific PROTAC from self-owned targeted protein degradation platform
Tags：
IMPACT THERAP-B07630.HKR&D Progress
2026-08-12
LAEKNA-B (02105.HK): NDA for LAE002 (Afuresertib) Accepted by NMPA for HR+/HER2- Breast Cancer
Tags：
LAEKNA-B02105.HKR&D Progress
2026-08-12
MICOT PHARMA-B (02335.HK): Preclinical and Phase I data of neuroprotective candidate MT200605 accepted for oral presentation at 2026 World Stroke Congress; Phase II meets primary endpoint
Tags：
Micot Pharma-B02335.HKR&D Progress
2026-08-11
KEYMED BIO-B (02162.HK): Phase II trial of CM512 (TSLP x IL-13 bispecific antibody) for chronic rhinosinusitis with nasal polyps meets all study endpoints; Phase III to advance with 300mg once-half-yearly regimen
Tags：
KEYMED BIO-B02162.HKR&D Progress
2026-08-10
GENFLEET-B (02595.HK): Phase III study of world's first oral KRAS G12D inhibitor for NSCLC initiated; second registrational clinical study of GFH375 completes first patient enrolment
Tags：
GENFLEET-B02595.HKR&D Progress
2026-08-10
GRANDPHARMA (00512.HK): Innovative RDC Drug GPN01530-2 Granted FDA Fast Track Designation for Diagnosis of Solid Tumors
Tags：
GRANDPHARMA00512.HKR&D Progress
2026-08-09
LUZHU BIOTECH-B (02480.HK): Phase III Results of Shingles Vaccine LZ901 Published in Nature Communications, Overall Vaccine Efficacy of 91.6%
Tags：
LUZHU BIOTECH-B02480.HKR&D Progress
2026-08-09
SBP GROUP (01177.HK): New Indication of Benmelstobart plus Chemotherapy Sequentially with Anlotinib as First-Line Treatment for Squamous NSCLC Approved for Marketing
Tags：
SBP GROUP01177.HKR&D Progress
2026-08-07
EDDING GENOR (06998.HK): First subject dosed in Phase Ib/II trial of trispecific antibody GB268 for breast cancer
Tags：
EDDING GENOR06998.HKR&D Progress
2026-08-07
CARSGEN-B (02171.HK): Universal CAR-T product CT1190B receives NMPA IND approval for treatment of relapsed/refractory large B-cell lymphoma
Tags：
CARSGEN-B02171.HKR&D Progress
2026-08-07
Previous1..2345 6